BioNTech Annual General Meeting Vaccine effective against mutants

Status: 06/22/2021 6:13 p.m.

BioNTech boss Sahin uses the vaccine manufacturer’s general meeting to spread good news: Production will be increased and the vaccine also protects against virus variants. In view of the growing spread of the delta variant of the coronavirus, which is considered to be more dangerous, many people are wondering how the effectiveness of the various vaccines is doing in this regard. At today’s Annual General Meeting, CEO Ugur Sahin gave the all-clear for BioNTech’s product: “There is currently no evidence that our vaccine needs to be adapted to the variants in circulation,” he said. That does not mean that the company is stopping development: According to Sahin, BioNTech is working on flexible processes in the areas of technology, production and approval.

06/22/2021

BioNTech Annual General Meeting Successful with mRNA technology

At today’s Annual General Meeting, the BioNTech top management can boast great successes.

Constant analysis

In order to be prepared and to be able to react quickly if a third dose should be required to boost existing vaccinations or to adapt to a new virus strain, BioNTech constantly analyzes the effectiveness of the vaccine against newly emerging variants, the CEO explained.

Sahin also commented on the subject of booster vaccinations: It is not yet known when and how often a booster will be necessary. But he assumes “that a third vaccination is of great value for boosting immunity,” said Sahin. Knowledge about the corona virus is steadily increasing. “We observe that immunity will decrease over time and new variants will emerge.”

June 21, 2021

EY study Corona is changing the pharmaceutical industry

The pandemic did not give the industry a boost in 2020, it actually slowed it down.

Sahin against patent release

The one raised by US President Joe Biden and other politicians Request for the release of patents to enable license-free vaccine production in developing countries, the BioNTech boss rejected. It is important to be able to make the vaccine available worldwide “as quickly and as comprehensively as possible”. However, raw materials are currently the “limiting factor”, not patents.

BioNTech is working with partners to deliver the vaccine cheaply to developing countries. However, a patent release would not bring additional amounts of vaccine. The production of the vaccine is very complex and consists of around 50,000 work steps.

05/28/2021

European Medicines Agency Green light for BioNTech vaccine from the age of twelve

The vaccine is “well tolerated” and there are no “serious concerns” about possible side effects.

Production is increased

During the Annual General Meeting, Sahin also commented on production: The BioNTech boss confirmed that the company, together with its US partner Pfizer, is aiming for a production capacity of up to three billion vaccine doses this year.

In the coming year 2022 it should be more than three billion. BioNTech will manufacture at least half of this. To date, BioNTech and Pfizer have shipped more than 700 million doses of their Covid-19 vaccine to over 100 countries worldwide.

05/08/2021

Up to 1.8 billion vaccine doses EU bulk purchase at BioNTech / Pfizer

The EU will buy 900 million doses of the BioNTech / Pfizer vaccine, with the option of purchasing another 900 million.

Dividend is possible

The shareholders should also benefit from the billions in sales generated with the corona vaccine. Chief Financial Officer Sierk Poetting said that in the next financial year it should be checked whether and in what amount a dividend is possible.

However, the strategic priority for 2021 is the reinvestment of the capital in order to further advance innovations in various therapeutic areas and technologies as well as our corporate development, said Poetting. The Mainz biotechnology company achieved a net profit of 1.1 billion euros on sales of 2.05 billion euros in the first quarter of this year .

05/10/2021

Sales multiplied Billions in profit for BioNTech

The biotech company benefited greatly from its Covid-19 vaccine Comirnaty in the first quarter.

New production facilities

There was also news from BioNTech outside of the Annual General Meeting. The European Medicines Agency’s Committee on Medicinal Products for Human Use gives the go-ahead for two more production facilities to manufacture the joint corona vaccine from Biontech and Pfizer.

One becomes accordingly in Reinbek, Schleswig-Holstein, operated by Allergopharma, the parent company of Dermapharm , the other in the Swiss stone from Novartis Pharma. The work can be started immediately, since no approval from the EU Commission is required